Alexion ups guidance

Alexion Pharmaceuticals (ALXN) ups its 2014 EPS guidance to $4.37 to $4.47 from $3.70 - $3.80 citing improved reimbursement for Soliris in France.

Revenue guidance now $2.15B - $2.17B up from $2B - $2.02B.

Shares are up almost 3% premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs